News

• 03.01.2019

  Exploiting pathway dependence in HCL and HCL variant (extension of 2018 grant)

  Ex-vivo drug treatment with pathway inhibitors can be exploited to map signaling pathways that HCL cells depend on. Combination effects can then be used to build individual patient`s cellular “signaling maps”, which will foster personalized treatment approaches. By studying the effects of inhibitors on cellular structure, signaling an gene expression we envision to understand major disease drivers of both HCL and HCL variant. mehr
• 03.01.2019

  Congratulations to Paul Kachel

  Congratulations to Paul Kachel for receiving a competitive Helmut Horten Foundation grant on the project “Drug Response in Patients with Multiple Myeloma”! mehr
• 21.12.2018

  Congratulations to Alessandra Curioni

  Congratulations to Alessandra Curioni for receiving a 36 months Swiss Cancer League grant on the topic "Development of new therapies for mesothelioma: learning from pre-clinical models to design clinical trials”! mehr